DelveInsight's "Obesity - Epidemiology Forecast-2032" report delivers an in-depth understanding of the obesity, historical and forecasted epidemiology as well as the obesity trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.
- The United States
- EU5 (Germany, France, Italy, Spain, and the United Kingdom)
Study Period: 2019-2032
The DelveInsight’s obesity epidemiology report gives a thorough understanding of obesity. Obesity is defined as an abnormal or excessive accumulation of fat or adipose tissue in the body that presents a risk to health. The body mass index (BMI) is used to define obesity, which is calculated as weight (kg)/height (m2). A person with a body mass index greater than or equal to 30 is considered obese (WHO, 2022a). It is the second most common cause of preventable death, which has its association with the risk of development of inflammatory components, directly and indirectly, related to cardiovascular disease, diabetes mellitus, respiratory problems, psychological issues, hypertension, obstructive sleep apnea, cancer, and hyperlipidemia. It imposes a significant public health epidemic that has progressively worsened over the past semi-centennial. An increase in obesity has been observed in children as well as adults of both genders and is prevalent in both developed and developing countries.
Compared to other chronic diseases, obesity results from an interaction between an individual’s genetic predisposition to weight gain and environmental influences. Gene discovery in the field of weight regulation and obesity has identified several major single-gene effects resulting in severe and early-onset obesity, as well as many more minor genes with more variable effects on weight and fat distribution, including age-of-onset and severity.
The most visible sign of obesity can be derived from the magnitude of excess adipose tissue fat, which is measured by taking anthropometric measurements such as body mass index (BMI), waist circumference, and others.
Body mass index, also known as Quetelet index, is defined as a person’s weight in kilograms divided by the square of his height in meters (kg/m2). For adults, a person is considered obese if they have BMI greater than or equal to 30. Whereas for children under 5 years of age, obesity is considered when weight-for-height is greater than three standard deviations above the WHO Child Growth Standards median. For children aged between 5–19 years of age, obesity is considered when weight-for-height is greater than two standard deviations above the WHO Growth Reference median.
Diagnosis of obesity involves proper evaluation of the weight status, which considers many factors and uses various tools and diagnostic tests, including body mass index (BMI), waist circumference measurement, physical exams, and lab tests to check for comorbidities.
The epidemiology section provides insights about the historical and current obesity patient pool and forecasted trends for individual seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends along with assumptions undertaken.
The disease epidemiology covered in the report provides a historical as well as forecasted obesity epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2019 to 2032.
In the year 2021, the total prevalent cases of obesity in adults (>19years) were 182.22 million and in children (5–19 years) were 7.85 million in the 7MM which are expected to grow during the study period, i.e., 2019–2032.
The disease epidemiology covered in the report provides historical as well as forecasted obesity epidemiology [segmented as total prevalent cases of obesity, total obesity patients seeking help, total treated cases of obesity] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
Country Wise- Obesity Epidemiology
The epidemiology segment also provides the obesity epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
To keep up with the current obesity patient pool and forecasted trend, we take KOLs and SMEs ' opinions working in the obesity domain through primary research to fill the data gaps and validate our secondary research. Their opinion helps to understand and validate the patient pool and forecasted trend.
Get a more detailed overview of How the Obesity Market will evolve in the upcoming years: Obesity Market Outlook and Forecast
Scope of the Report
- The report covers the descriptive overview of obesity, explaining their causes, symptoms, pathophysiology, and genetic basis.
- The report provides insight into the 7MM historical and forecasted patient pool covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan.
- The report assesses the disease risk and burden and highlights the unmet needs of obesity.
- The report helps to recognize the growth opportunities in the 7MM concerning the patient population.
- The report provides the segmentation of the disease epidemiology for 7MM Total prevalent Cases of obesity, Total obesity patients seeking help, Total Treated Cases of obesity in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2019 to 2032.
- The companies and academics are working to assess challenges and seek opportunities that could influence obesity R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition.
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for obesity
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.
Obesity Report Key Strengths
- 11 Years Forecast
- 7MM Coverage
- Obesity Epidemiology Segmentation
- What are the disease risk, burden, and regional/ethnic differences of obesity?
- What are the key factors driving the epidemiology trend for seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What is the historical obesity patient pool in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- What would be the forecasted patient pool of obesity in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan?
- Where will be the growth opportunities in the 7MM concerning the patient population about obesity?
- Out of all 7MM countries, which country would have the highest incident population of obesity during the forecast period (2019-2032)?
- At what CAGR the patient population is expected to grow by 7MM during the forecast period (2019-2032)?
Reasons to buy
- The report will help in developing business strategies by understanding trends shaping and driving the obesity Disease market
- To understand the future market competition in the obesity Disease market and Insightful review of the key market drivers and barriers
- Organize sales and marketing efforts by identifying the best opportunities for obesity Disease in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom), and Japan
- Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
- Organize sales and marketing efforts by identifying the best opportunities for the obesity Disease market
- To understand the future market competition in the obesity Disease market